Gastric juice miR-129 as a potential biomarker for screening gastric cancer

MicroRNAs (miRNAs) play crucial roles during the occurrence and development of gastric cancer. Conventional serological tests for screening gastric cancer have limits on sensitivity and specificity. Several miRNAs in peripheral blood have been used as biomarkers of gastric cancer. However, most of these miRNAs are shared by several types of cancer. Thanks to the tissue specificity of gastric juice, here we examined the feasibility of using gastric juice miR-129-1/2, which are aberrantly expressed in gastric cancer, to screen gastric cancer. Total of 141 gastric juices samples from gastric cancer, gastric ulcer, atrophic gastritis, and minimal gastritis patients or subjects with normal mucosa were collected by gastroscopy. The gastric juice miR-129-1/2 levels were detected by quantitative reverse transcription-polymerase chain reaction. A receiver operating characteristic (ROC) curve was constructed for differentiating patients with gastric cancer from patients with benign gastric diseases. We showed that, compared with patients with benign gastric diseases, patients with gastric cancer had significantly lower levels of gastric juice miR-129-1-3p and miR-129-2-3p. The areas under ROC curve (AUC) were 0.639 and 0.651 for miR-129-1-3p and miR-129-2-3p, respectively. Using the parallel combination test, the AUC was up to 0.656. In summary, our results suggest that gastric juice miR-129-1-3p and miR-129-2-3p are potential biomarkers for the screening gastric cancer, and the detection of gastric juice miRNAs is a convenient non-invasion method for the diagnosis of gastric cancer.

[1]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[2]  Ying Chen,et al.  Rapid high‐performance liquid chromatography method for determination of tryptophan in gastric juice , 2012, Journal of digestive diseases.

[3]  Y. Fujii,et al.  microRNA expression profile in undifferentiated gastric cancer. , 2009, International journal of oncology.

[4]  K. Souto,et al.  Prevalence of upper digestive endoscopy and gastric histopathology findings in morbidly obese patients. , 2012, Arquivos de gastroenterologia.

[5]  Avrum Spira,et al.  miR-129 regulates cell proliferation by downregulating Cdk6 expression. , 2010, Cell cycle.

[6]  X. Agirre,et al.  Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues , 2006, Molecular Cancer.

[7]  Xi Chen,et al.  A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. , 2011, European journal of cancer.

[8]  D. Hoskovec,et al.  Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers. , 2012, Acta cirurgica brasileira.

[9]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[10]  Y. Tan,et al.  Early diagnosis of early gastric cancer. , 2006, European journal of gastroenterology & hepatology.

[11]  B. Xiao,et al.  Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance , 2010, Medical oncology.

[12]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[13]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[14]  Wei Li,et al.  Plasma microRNAs, miR-223, miR-21 and miR-218, as Novel Potential Biomarkers for Gastric Cancer Detection , 2012, PloS one.

[15]  Zhenggang Zhu,et al.  microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN , 2012, Oncology reports.

[16]  A. Schetter,et al.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.

[17]  M. Rugge,et al.  Clinical usefulness of gastric-juice analysis in 2007: the stone that the builders rejected has become the cornerstone. , 2007, Gastrointestinal endoscopy.

[18]  S. Fujieda,et al.  Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. , 2010, Oncology reports.

[19]  Kazuhiro Yoshida,et al.  Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. , 2010, The Lancet. Oncology.

[20]  B. Xiao,et al.  Differential expression of microRNA species in human gastric cancer versus non‐tumorous tissues , 2009, Journal of gastroenterology and hepatology.

[21]  Jason H. Moore,et al.  Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. , 2007, Cancer research.

[22]  B. Xiao,et al.  Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using piRNAs as markers. , 2010, Clinical biochemistry.

[23]  Alicia Algeciras-Schimnich,et al.  Analysis of circulating microRNA: preanalytical and analytical challenges. , 2011, Clinical chemistry.

[24]  H. Shin,et al.  Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  Hai-rim Shin,et al.  Cancer control in the Asia Pacific region: current status and concerns. , 2012, Japanese journal of clinical oncology.

[26]  P. Malfertheiner,et al.  Serological assessment of gastric mucosal atrophy in gastric cancer , 2012, BMC Gastroenterology.

[27]  Xiaoling Lin,et al.  Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. , 2010, Biochemical and biophysical research communications.

[28]  Xinjun Zhang,et al.  Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker , 2010, Journal of Molecular Medicine.

[29]  Sung-Chou Li,et al.  Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells , 2012, Carcinogenesis.

[30]  Shaoxiang Zhang,et al.  MicroRNAs play a role in the development of human hematopoietic stem cells , 2008, Journal of cellular biochemistry.

[31]  Zhenggang Zhu,et al.  Macroscopic Borrmann Type as a Simple Prognostic Indicator in Patients with Advanced Gastric Cancer , 2009, Oncology.

[32]  Jingqin Luo,et al.  Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. , 2009, Cancer research.

[33]  Japanese Gastric Cancer Association.  Japanese Classification of Gastric Carcinoma – 2nd English Edition – , 1998, Gastric Cancer.

[34]  B. Xiao,et al.  MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[35]  A. Farcomeni,et al.  MicroRNA profiling in human medulloblastoma , 2009, International journal of cancer.

[36]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Costamagna,et al.  Early gastric cancer: detection and endoscopic treatment. , 2012, Annali italiani di chirurgia.

[38]  B. Jobe,et al.  Endoscopy and role of endoscopic resection in gastric cancer , 2013, Journal of surgical oncology.

[39]  Junming Guo,et al.  MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. , 2011, Cancer biomarkers : section A of Disease markers.

[40]  W. Wassef,et al.  An update in endoscopic management of gastric cancer , 2011, Current opinion in gastroenterology.

[41]  N. Duraker,et al.  The prognostic significance of gastric juice CA 19-9 and CEA levels in gastric carcinoma patients. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.